Combined immunophenotyping and fluorescence in situ hybridization with chromosome-specific DNA probes allows quantification and differentiation of ex vivo generated dendritic cells, leukemia-derived dendritic cells and clonal leukemic cells in patients with acute myeloid leukemia

References

• Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 2000;243:59–75.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Minev BR, Taggarse AS, et al. Enhancing the recognition of tumor associated antigens. Folia Biol (Praha) 1993;40:74–88.
   Web of Science ®Google Scholar
• Brossart P. Dendritic cells in vaccination therapies of malignant diseases. Transfus Apheresis Sci 2002;27:183–186.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from the bench to bedside. Nat Med 2001;7:761–765.
   PubMed Web of Science ®Google Scholar
• Dreyßig J, Kremser A, Kufner S, et al. Expression profiles of leukemia-derived dendritic cells in AML and MDS depending on different culture conditions. Immunotherapy 2011;3:1113–1124.
   PubMed Web of Science ®Google Scholar
• Kremser A, Dreyßig J, Grabrucker C, et al. Dendritic cells can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother 2010;33:185–199.
   PubMed Web of Science ®Google Scholar
• Schmetzer HM, Kremser A, Loibl J, et al. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC (“DCleu”) contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia 2007;21:1338–1341.
   PubMed Web of Science ®Google Scholar
• Grabrucker C, Liepert A, Dreyssig J, et al. The quality and quantity of leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are a predictive factor for the lytic potential of DC-primed leukemia-specific T-cells. J Immunother 2010;33:523–537.
   PubMed Web of Science ®Google Scholar
• Liepert A, Grabrucker C, Kremser A, et al. Quality of T-cells after priming with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Cell Immun 2010;265:23–30.
   PubMed Web of Science ®Google Scholar
• Dehlin B, Duell T, Schmid C, et al. Clonality-from diagnosis towards therapeutic options in malignant hematopoetic disorders: overview and case report. Acta Haematol 2008;116:131–136.
   Google Scholar
• Grimwade D, Mrózek K. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol Oncol Clin North Am 2011;25:1135–1161
   PubMed Web of Science ®Google Scholar
• Hessel H, Mittermüller J, Zitzelsberger H, et al. Combined immunophenotyping and FISH with sex chromosome-specific DNA probes for the detection of chimerism in epidermal Langerhans cells after sex-mismatched bone marrow transplantation. Histochem Cell Biol 1996;106:481–485.
   PubMed Web of Science ®Google Scholar
• Kufner S, Fleischer RP, Kroell T, et al. Serum-free generation and quantification of functionally active leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother 2005; 54:953–970.
   PubMed Web of Science ®Google Scholar
• Hayhoe FG. Classification of acute leukemia. Blood Rev 1988;2:186–193.
   PubMed Web of Science ®Google Scholar
• Graf M, Reif S, Hecht K, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol 2005;84:287–297.
   PubMed Web of Science ®Google Scholar
• Schmetzer H. Dendritic cells as prognostic indicators or as immunotherapeutic tools to treat acute myeloid leukemia (AML) and high grade myelodysplasia (MDS). Review. Recent Adv Res Updat 2008;9:125–137.
   Google Scholar
• Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2002;23:592–595.
   Google Scholar
• Nguyen XD, Eichler H, Dugrillon A, et al. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. J Immunol Methods 2003;9281:1–12.
   Google Scholar
• Weber-Matthiesen K, Winkemann M, Müller-Hermelink A, et al. Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem 1992;40:171–175.
   PubMed Web of Science ®Google Scholar
• Zitzelsberger H, Szücs S, Weier HU, et al. Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in situ hybridizitation (FISH) on paraffin-embedded tissue section with centromere-specific DNA probes. J Pathol 1994;172:325–335.
   PubMed Web of Science ®Google Scholar
• Kolb H-J, Schmid C, Barrett A, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767–776.
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic SCT. Blood 2012;119:1599–1606.
   PubMed Web of Science ®Google Scholar
• Schmetzer H, Schmid C. The T-cells’ role in anti-leukaemic reactions - perspectives for future therapies. In: Demirer T, editor . New advances in stem cell transplantation. Rijeka: InTech; 2012. pp. 959–982. Available from: http://www.intechopen.com/books/new-advances-in-stemcell-transplantation/the-t-cells-role-in-anti-leukaemic-reactions-perspectives-for-future-therapies-
   Google Scholar
• Schmetzer H. Antileukemic T-cell-mediated immune reactions: limitations and perspectives for future therapies. Immunotherapy 2011;3:809–811.
   PubMed Web of Science ®Google Scholar
• Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783–1786.
   Google Scholar
• Graf M, Reif S, Hecht K, et al. High expression of costimulatory molecules correlates with low relapse free-survival-probability in acute myeloid leukemia (AML). Ann Hematol 2005;84:287–297.
   PubMed Web of Science ®Google Scholar
• Schmetzer HM, Poleck B, Mittermueller J, et al. Clonality analysis as a tool to study the biology and response to therapy in myelodysplastic syndromes. Leukemia 1997;11:660–666.
   PubMed Web of Science ®Google Scholar
• Freudenreich M, Schmid C, Kremser A, et al. Clinical relevance of in vitro generation of Dendritic cells in patients with AML or MDS. Bone Marrow Transplant 2010;45(Suppl. 2): Abstract 959.
   Google Scholar